| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| NeuBase Therapeutics, Inc. | Chief Financial Officer | Common stock | 84,200 | $161,664 | $1.92 | 16 Mar 2023 | Direct |
| NeuBase Therapeutics, Inc. | Chief Financial Officer | Stock option (right to buy) | 200,000 | 03 Nov 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| NBSE | NeuBase Therapeutics, Inc. | 16 Mar 2023 | 1 | $0 | 4 | Chief Financial Officer | 17 Mar 2023, 16:11 |
| NBSE | NeuBase Therapeutics, Inc. | 03 Nov 2022 | 1 | $0 | 4 | Chief Financial Officer | 04 Nov 2022, 17:00 |
| NBSE | NeuBase Therapeutics, Inc. | 18 Mar 2022 | 1 | $18,100 | 4 | Chief Financial Officer | 21 Mar 2022, 16:06 |
| NBSE | NeuBase Therapeutics, Inc. | 16 Mar 2022 | 2 | $33,600 | 4 | Chief Financial Officer | 18 Mar 2022, 16:11 |
| NBSE | NeuBase Therapeutics, Inc. | 10 Jan 2022 | 1 | $0 | 4 | Chief Financial Officer | 10 Jan 2022, 18:19 |
| NBSE | NeuBase Therapeutics, Inc. | 10 Jan 2022 | 0 | $0 | 3 | Chief Financial Officer | 10 Jan 2022, 18:15 |